Statements (18)
Predicate | Object |
---|---|
gptkbp:instanceOf |
gptkb:biotechnology
|
gptkbp:approvalYear |
2021
|
gptkbp:CEO |
gptkb:Rachelle_Jacques
|
gptkbp:developedBy |
RYZUMVI
RYZUMVI (allogeneic processed thymus tissue-agdc) |
gptkbp:focusesOn |
regenerative medicine
rare diseases |
gptkbp:foundedYear |
2016
|
gptkbp:headquartersLocation |
gptkb:Durham,_North_Carolina,_United_States
|
https://www.w3.org/2000/01/rdf-schema#label |
Enzyvant
|
gptkbp:industry |
gptkb:biotechnology
|
gptkbp:parentCompany |
gptkb:Sumitomo_Pharma
|
gptkbp:previousOwner |
gptkb:Roivant_Sciences
|
gptkbp:receivedFDAApprovalFor |
RYZUMVI
|
gptkbp:specializesIn |
cell and gene therapies
|
gptkbp:website |
https://www.enzyvant.com/
|
gptkbp:bfsParent |
gptkb:ROIV
|
gptkbp:bfsLayer |
6
|